Side Effects of COVID-19 Vaccinations

Introduction

Vaccines are one of the most effective approaches for eliminating COVID-19, saving millions of lives annually. Furthermore, the optimal choice is a safe and effective vaccination with minimal side effects. The absence of an effective and licenced COVID-19 therapy has sparked a vaccination research race, with 259 COVID-19 vaccine projects beginning on November 11, 2020. Rapid vaccine development has increased the potential for safety hazards [1]. On January 14, 2021, people started getting baseline and monthly surveys inquiring if they had ever had a COVID-19 (SARS-CoV-2) vaccination. After a subject reported getting a vaccine, follow-up questions inquired about the number of doses, dates, brand, and location of the vaccination. Volunteers were asked to complete a monthly follow-up survey about obtaining extra vaccination doses. Monthly surveys were used to reduce participant burden and accommodate vaccination delivery regimens that separated doses by 3–4 weeks. . Partial immunisation was defined as getting one dose of any vaccine except JNJ-78436735 (Johnson & Johnson). Full immunisation was defined as getting 1 dose of JNJ- 78436735 or 2 doses of any other vaccine. Data on further doses were not gathered since third or booster doses had not yet been advised at the time of collection. Only subjects who reported getting BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), or JNJ-78436735 vaccinations were included in the final analysis, as other vaccines were not widely used in this trial. Participants were asked to report any adverse effects of vaccination, including fever, chills, fatigue, sore throat, muscle pain, joint pain, headache, other pain, redness or swelling at the injection site, rash elsewhere, allergic reaction or anaphylaxis, and none of the above. The response options were chosen based on reported adverse effects in vaccination clinical studies. Participants could offer free-text replies to the choice of “other.” Participants who reported adverse effects were questioned about their duration and self-rated severity (very mild, mild, moderate, severe, or very severe) [2, 3].

On January 3, 2021, the Drugs Controller General of India (DCGI) approved the Bharat biotech vaccine against COVID-19, a locally manufactured inactivated vaccine named ‘’COVAXIN’’ in collaboration with the Indian Council of Medical Research (ICMR), for emergency use alongside the Covishield Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India.

Conclusion

An intriguing finding from our research is that, despite the fact that the topic of discussion is the vaccine’s side effects, just 21.3% of the tweets about them expressed negative opinions. Nonetheless, it is crucial for the Indian government and non-governmental organisations to assist in enlightening the public about their shared concerns regarding the adverse impacts of COVID-19 vaccinations on social media [9].

Recent research has revealed that the following fears exist: the fear that receiving the COVID-19 vaccine will affect one’s productivity at work; the fear that receiving the vaccine could result in death; the fear that receiving the vaccine carries a risk; the fear that receiving the vaccine will have long-term consequences; the fear that receiving the vaccine will have an adverse effect on one’s health; the fear that a blood clot will occur; the fear stoked by the media; the safety precautions at the vaccination site; and the effectiveness of the vaccine [10].

Since the onset of the COVID-19 crisis, several studies have been undertaken to determine the best ways to comprehend the general public’s perspective of the psychological consequences of COVID-19 as well as the most effective approaches to cope with it [11]. With the collapse of the first wave and the rapid rise of the second wave, government officials and policymakers must grasp how public opinion of various components of the crisis evolves over time. It is critical for governments all around the world to vigorously accelerate the immunisation programme to avert the third and maybe fourth waves of the COVID-19 disaster [11, 12].